55 results
Medicine type
Generic Remove Generic filter
Additional monitoring Remove Additional monitoring filter
Conditional approval Remove Conditional approval filter
Orphan medicine Remove Orphan medicine filter
Biosimilar Remove Biosimilar filter
Categories
Human Remove Human filter
-
List item
Summary of opinion: Zynlonta (updated)
loncastuximab tesirine, opinion date: 15/09/2022, Positive, Last updated: 19/09/2022 -
List item
Summary of opinion: Tuznue
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 24/06/2022 -
List item
Summary of opinion: Hervelous
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 24/06/2022 -
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Ertapenem SUN
ertapenem, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Crysvita
burosumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Ranivisio
ranibizumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Ultomiris
ravulizumab, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Tecartus
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Imcivree
setmelanotide, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Adtralza (new)
tralokinumab, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Teriflunomide Accord (new)
teriflunomide, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Skyrizi (new)
risankizumab, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Ximluci (new)
ranibizumab, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Biktarvy (new)
bictegravir, emtricitabine, tenofovir alafenamide, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Sorafenib Accord (new)
sorafenib, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Brukinsa (new)
zanubrutinib, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Vaxneuvance (new)
pneumococcal polysaccharide conjugate vaccine (adsorbed), opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Pyrukynd (new)
mitapivat, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Yescarta (new)
axicabtagene ciloleucel, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Enjaymo (new)
sutimlimab, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Teriflunomide Mylan (new)
teriflunomide, opinion date: 15/09/2022, Positive, Last updated: 16/09/2022 -
List item
Summary of opinion: Vegzelma
bevacizumab, opinion date: 23/06/2022, Positive, Last updated: 21/06/2022 -
List item
Direct healthcare professional communication (DHPC): Respreeza (human alpha-1-proteinase inhibitor): Batch-specific product recall
Active substance: alpha1-proteinase inhibitor (human), DHPC type: Quality defect, Last updated: 12/02/2021